Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0

作者：

Wallace, Daniel J. ^{[1
]}

Furie, Richard ^{[2
]}

Tanaka, Yoshiya ^{[3
]}

Kalunian, Kenneth C. ^{[4
]}

Mosca, Marta ^{[5
]}

Petri, Michelle ^{[6
]}

Dorner, Thomas ^{[7
,8
]}

Cardiel, Mario H. ^{[9
]}

Bruce, Ian N. ^{[10
]}

Gomez, Elisa ^{[11
]}

DeLozier, Amy M. ^{[11
]}

Janes, Jonathan ^{[11
]}

Linnik, Matthew D. ^{[11
]}

de Bono, Stephanie ^{[11
]}

Silk, Maria E. ^{[11
]}

Hoffman, Robert W. ^{[11
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA

[2] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA

[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

[5] Univ Pisa, Pisa, Italy

[6] Johns Hopkins Univ, Sch Med, Med Rheumatol, Baltimore, MD USA

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Deutsch Rheumaforschungszentrum DRFZ, Berlin, Germany

[9] Ctr Invest Clin Morelia SC, Morelia, Michoacan, Mexico

[10] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Ctr Musculoskeletal Res, Manchester, Lancs, England

[11] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

970

引用

页数：2

共 50 条

[11] Memantine in Systemic Lupus Erythematosus: A Randomized, Double-Blind Placebo-Controlled Trial
Petri, Michelle
Naqibuddin, Mohammad
Sampedro, Margaret
Omdal, Roald
Carson, Kathryn A.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 194 - 202
[12] A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus
Werth, V. P.
Merrill, J. T.
BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 964 - 965
[13] LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study
Alarcón-Segovia, D
Tumlin, JA
Furie, RA
McKay, JD
Cardiel, MH
Strand, V
Bagin, RG
Linnik, MD
Hepburn, B
ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 442 - 454
[14] BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Doerner, T.
Van Vollenhoven, R.
Doria, A.
Jia, B.
Fantini, D.
Terres, J. Ross
Silk, M.
De Bono, S.
Fischer, P.
Wallace, D. J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 588 - 589
[15] BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Maney, Nicola
Doerner, Thomas
van Vollenhoven, Ronald F.
Doria, Andrea
Jia, Bochao
Fantini, Damiano
Terres, Jorge A. Ross
Silk, Maria E.
de Bono, Stephanie
Fischer, Peter
Wallace, Daniel J.
RHEUMATOLOGY, 2022, 61 : I131 - I131
[16] POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS
Dorner, T.
Tanaka, Y.
Mosca, M.
Bruce, I. N.
Cardiel, M.
Morand, E. F.
Petri, M. A.
Silk, M.
Dickson, C.
Meszaros, G.
Issa, M.
Zhang, L.
Wallace, D. J.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 639 - 639
[17] Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Doerner, Thomas
Van Vollenhaven, Ronald
Doria, Andrea
Jia, Bochao
Fantini, Damiano
Terres, Jorge Ross
Silk, Maria
de Bono, Stephanie
Fischer, Peter
Wallace, Daniel
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3640 - 3642
[18] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018)
Wallace, D. J.
Furie, R. A.
Tanaka, Y.
LANCET, 2018, 392 (10146): : 476 - 476
[19] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES
Morand, E. F.
Tanaka, Y.
Furie, R.
Vital, E.
van Vollenhoven, R.
Kalunian, K.
Mosca, M.
Doerner, T.
Wallace, D. J.
Silk, M.
Dickson, C.
De la Torre, I.
Meszaros, G.
Jia, B.
Crowe, B.
Petri, M. A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 327 - 328
[20] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Petri, Michelle
Bruce, Ian N.
Doerner, Thomas
Tanaka, Yoshiya
Morand, Eric F.
Kalunian, Kenneth C.
Cardiel, Mario H.
Silk, Maria E.
Dickson, Christina L.
Meszaros, Gabriella
Zhang, Lu
Jia, Bochao
Zhao, Youna
McVeigh, Conor J.
Mosca, Marta
LANCET, 2023, 401 (10381): : 1011 - 1019

← 1 2 3 4 5 →